DEDUCT | Database of Endocrine Disrupting chemicals and their Toxicity profiles

Tetramethylthiuram disulfide

ToxCast endpoints for intended target type: RNA

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CLD_CYP1A1_24hr	Liver	Human	1543	CYP1A1	Gain	35.91 μM
CLD_CYP1A1_48hr	Liver	Human	1543	CYP1A1	Gain	30.82 μM
CLD_CYP1A2_48hr	Liver	Human	1544	CYP1A2	Gain	34.77 μM
LTEA_HepaRG_CYP2B6	Liver	Human	1555	CYP2B6	Activatory	50.0 μM

ToxCast endpoints for intended target type: Protein

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CCTE_Deisenroth_TSHR_2D_Antag_TG_PROT	Thyroid	Human	7253	TSHR	Activatory	34.9 μM
NVS_ADME_hCYP2C18		Human	1562	CYP2C18	Loss	1.94 μM
NVS_ADME_hCYP2C9		Human	1559	CYP2C9	Loss	1.92 μM
NVS_ADME_hCYP2D6		Human	1565	CYP2D6	Loss	2.14 μM
NVS_ADME_hCYP2J2		Human	1573	CYP2J2	Loss	6.56 μM
NVS_ADME_rCYP2A1		Rat	24894	Cyp2a1	Loss	2.8 μM
NVS_ADME_rCYP2C12		Rat	25011	Cyp2c12	Loss	1.98 μM
NVS_ADME_rCYP3A1		Rat	25642	Cyp3a23-3a1	Loss	3.2 μM
NVS_ADME_rCYP3A2		Rat	266682	Cyp3a2	Loss	2.42 μM
NVS_ENZ_hAChE		Human	43	ACHE	Loss	9.41 μM
NVS_ENZ_hSIRT1		Human	23411	SIRT1	Loss	8.32 μM
NVS_ENZ_rACFSKBinding	Brain	Rat	64532	Adcy5	Loss	9.01 μM
NVS_GPCR_h5HT6		Human	3362	HTR6	Loss	5.18 μM
NVS_GPCR_h5HT7		Human	3363	HTR7	Loss	9.36 μM
NVS_GPCR_hDRD1		Human	1812	DRD1	Loss	4.51 μM
NVS_GPCR_hNPY1		Human	4886	NPY1R	Loss	14.69 μM
NVS_GPCR_hOpiate_mu		Human	4988	OPRM1	Loss	3.42 μM
NVS_MP_rPBR	Kidney	Rat	24230	Tspo	Loss	10.31 μM
NVS_NR_hFXR_Antagonist		Human	9971	NR1H4	Loss	10.68 μM
BSK_3C_Eselectin	Vascular	Human	6401	SELE	Inhibitory	30.48 μM
BSK_3C_HLADR	Vascular	Human	3122	HLA-DRA	Inhibitory	14.88 μM
BSK_3C_ICAM1	Vascular	Human	3383	ICAM1	Inhibitory	32.07 μM
BSK_3C_IL8	Vascular	Human	3576	CXCL8	Inhibitory	31.73 μM
BSK_3C_MCP1	Vascular	Human	6347	CCL2	Inhibitory	30.86 μM
BSK_3C_MIG	Vascular	Human	4283	CXCL9	Inhibitory	33.65 μM
BSK_3C_Thrombomodulin	Vascular	Human	7056	THBD	Inhibitory	36.66 μM
BSK_3C_TissueFactor	Vascular	Human	2152	F3	Inhibitory	31.43 μM
BSK_3C_uPAR	Vascular	Human	5329	PLAUR	Inhibitory	29.37 μM
BSK_3C_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	16.94 μM
BSK_4H_Eotaxin3	Vascular	Human	10344	CCL26	Inhibitory	33.15 μM
BSK_4H_MCP1	Vascular	Human	6347	CCL2	Inhibitory	23.98 μM
BSK_4H_Pselectin	Vascular	Human	6403	SELP	Inhibitory	14.03 μM
BSK_4H_uPAR	Vascular	Human	5329	PLAUR	Inhibitory	26.34 μM
BSK_4H_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	29.25 μM
BSK_BE3C_HLADR	Lung	Human	3122	HLA-DRA	Inhibitory	8.68 μM
BSK_BE3C_IL1a	Lung	Human	3552	IL1A	Inhibitory	8.9 μM
BSK_BE3C_IP10	Lung	Human	3627	CXCL10	Inhibitory	10.72 μM
BSK_BE3C_MIG	Lung	Human	4283	CXCL9	Inhibitory	11.16 μM
BSK_BE3C_MMP1	Lung	Human	4312	MMP1	Inhibitory	14.16 μM
BSK_BE3C_PAI1	Lung	Human	5054	SERPINE1	Inhibitory	27.12 μM
BSK_BE3C_TGFb1	Lung	Human	7040	TGFB1	Inhibitory	12.93 μM
BSK_BE3C_tPA	Lung	Human	5327	PLAT	Inhibitory	12.01 μM
BSK_BE3C_uPA	Lung	Human	5328	PLAU	Inhibitory	8.85 μM
BSK_BE3C_uPAR	Lung	Human	5329	PLAUR	Inhibitory	9.57 μM
BSK_CASM3C_IL6	Vascular	Human	3569	IL6	Inhibitory	26.39 μM
BSK_CASM3C_MCP1	Vascular	Human	6347	CCL2	Inhibitory	20.0 μM
BSK_CASM3C_MCSF	Vascular	Human	1435	CSF1	Inhibitory	11.29 μM
BSK_CASM3C_MIG	Vascular	Human	4283	CXCL9	Inhibitory	14.57 μM
BSK_CASM3C_SAA	Vascular	Human	6288	SAA1	Inhibitory	12.33 μM
BSK_CASM3C_Thrombomodulin	Vascular	Human	7056	THBD	Inhibitory	10.16 μM
BSK_CASM3C_uPAR	Vascular	Human	5329	PLAUR	Inhibitory	30.49 μM
BSK_CASM3C_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	11.45 μM
BSK_hDFCGF_CollagenIII	Skin	Human	1281	COL3A1	Inhibitory	8.15 μM
BSK_hDFCGF_EGFR	Skin	Human	1956	EGFR	Inhibitory	5.9 μM
BSK_hDFCGF_IL8	Skin	Human	3576	CXCL8	Inhibitory	7.67 μM
BSK_hDFCGF_IP10	Skin	Human	3627	CXCL10	Inhibitory	2.74 μM
BSK_hDFCGF_MCSF	Skin	Human	1435	CSF1	Inhibitory	4.39 μM
BSK_hDFCGF_MIG	Skin	Human	4283	CXCL9	Inhibitory	3.01 μM
BSK_hDFCGF_MMP1	Skin	Human	4312	MMP1	Inhibitory	5.34 μM
BSK_hDFCGF_PAI1	Skin	Human	5054	SERPINE1	Inhibitory	5.64 μM
BSK_hDFCGF_TIMP1	Skin	Human	7076	TIMP1	Inhibitory	9.76 μM
BSK_hDFCGF_VCAM1	Skin	Human	7412	VCAM1	Inhibitory	4.12 μM
BSK_KF3CT_ICAM1	Skin	Human	3383	ICAM1	Inhibitory	6.42 μM
BSK_KF3CT_IL1a	Skin	Human	3552	IL1A	Inhibitory	6.44 μM
BSK_KF3CT_IP10	Skin	Human	3627	CXCL10	Inhibitory	6.1 μM
BSK_KF3CT_MCP1	Skin	Human	6347	CCL2	Inhibitory	5.09 μM
BSK_KF3CT_MMP9	Skin	Human	4318	MMP9	Inhibitory	7.1 μM
BSK_KF3CT_TGFb1	Skin	Human	7040	TGFB1	Inhibitory	8.71 μM
BSK_KF3CT_TIMP2	Skin	Human	7077	TIMP2	Inhibitory	6.4 μM
BSK_KF3CT_uPA	Skin	Human	5328	PLAU	Inhibitory	10.29 μM
BSK_LPS_CD40	Vascular	Human	958	CD40	Inhibitory	24.7 μM
BSK_LPS_Eselectin	Vascular	Human	6401	SELE	Inhibitory	28.51 μM
BSK_LPS_IL1a	Vascular	Human	3552	IL1A	Inhibitory	14.89 μM
BSK_LPS_IL8	Vascular	Human	3576	CXCL8	Inhibitory	26.55 μM
BSK_LPS_MCP1	Vascular	Human	6347	CCL2	Inhibitory	27.08 μM
BSK_LPS_MCSF	Vascular	Human	1435	CSF1	Inhibitory	14.8 μM
BSK_LPS_PGE2	Vascular	Human	5732	PTGER2	Inhibitory	4.5 μM
BSK_LPS_TissueFactor	Vascular	Human	2152	F3	Inhibitory	14.49 μM
BSK_LPS_TNFa	Vascular	Human	7124	TNF	Inhibitory	13.84 μM
BSK_LPS_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	24.58 μM
BSK_SAg_CD38	Vascular	Human	952	CD38	Inhibitory	26.76 μM
BSK_SAg_CD40	Vascular	Human	958	CD40	Inhibitory	27.96 μM
BSK_SAg_CD69	Vascular	Human	969	CD69	Inhibitory	28.29 μM
BSK_SAg_Eselectin	Vascular	Human	6401	SELE	Inhibitory	24.81 μM
BSK_SAg_IL8	Vascular	Human	3576	CXCL8	Inhibitory	18.27 μM
BSK_SAg_MCP1	Vascular	Human	6347	CCL2	Inhibitory	28.7 μM
BSK_SAg_MIG	Vascular	Human	4283	CXCL9	Inhibitory	36.6 μM
CCTE_GLTED_hDIO2		Human	1734	DIO2	Loss	55.74 μM
CCTE_GLTED_hDIO3		Human	1735	DIO3	Loss	40.67 μM
TOX21_ERa_BLA_Antagonist_ratio	Kidney	Human	2099	ESR1	Loss	33.67 μM
TOX21_GR_BLA_Antagonist_ratio	Cervix	Human	2908	NR3C1	Loss	33.09 μM
TOX21_TR_LUC_GH3_Antagonist	Pituitary gland	Rat	7067\|7068	THRA\|THRB	Loss	0.1 μM
TOX21_VDR_BLA_Antagonist_ratio	Kidney	Human	1591\|7421	CYP24A1\|VDR	Loss	10.71 μM
TOX21_RORg_LUC_CHO_Antagonist	Ovary	Chinese hamster	6097	RORC	Loss	0.13 μM
TOX21_TSHR_HTRF_Agonist_ratio	Kidney	Human	7253	TSHR	Gain	35.53 μM
TOX21_AChE_Fluor_Antagonist	Bone	Human	43	ACHE	Loss	3.43 μM
TOX21_p450_CYP3A4_Antagonist		Human	1576	CYP3A4	Loss	45.04 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	4.47 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	4.05 μM
TOX21_p450_CYP1A2_Antagonist		Human	1544	CYP1A2	Loss	3.42 μM
TOX21_AR_BLA_Agonist_ratio	Kidney	Human	367	AR	Gain	10.85 μM
TOX21_AR_BLA_Antagonist_ratio	Kidney	Human	367	AR	Loss	0.1 μM
TOX21_Aromatase_LUC_Antagonist	Breast	Human	1588	CYP19A1	Loss	0.06 μM
TOX21_GR_BLA_Antagonist_ratio	Cervix	Human	2908	NR3C1	Loss	67.24 μM
TOX21_RORg_LUC_CHO_Antagonist	Ovary	Chinese hamster	6097	RORC	Loss	0.08 μM
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881	Breast	Human	367	AR	Loss	0.12 μM
TOX21_TSHR_HTRF_Agonist_ratio	Kidney	Human	7253	TSHR	Gain	13.09 μM
TOX21_TSHR_HTRF_Antagonist_ratio	Kidney	Human	7253	TSHR	Loss	85.55 μM
TOX21_ERR_LUC_Antagonist	Kidney	Human	2101	ESRRA	Loss	0.14 μM
TOX21_ERb_BLA_Antagonist_ratio	Kidney	Human	2100	ESR2	Loss	0.11 μM
TOX21_PR_BLA_Antagonist_ratio	Kidney	Human	5241	PGR	Loss	0.15 μM
TOX21_AChE_Colorimetric_Antagonist	Bone	Human	43	ACHE	Loss	84.41 μM
TOX21_TRHR_HEK293_Antagonist	Kidney	Human	7201	TRHR	Loss	41.0 μM
TOX21_SBE_BLA_Antagonist_ratio	Kidney	Human	4086	SMAD1	Loss	0.15 μM
TOX21_p450_CYP3A4_Antagonist		Human	1576	CYP3A4	Loss	47.82 μM
TOX21_p450_CYP2D6_Antagonist		Human	1565	CYP2D6	Loss	4.35 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	5.09 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	5.74 μM
TOX21_p450_CYP1A2_Antagonist		Human	1544	CYP1A2	Loss	4.01 μM
TOX21_hERG_U2OS_Antagonist	Bone	Human	3757	KCNH2	Loss	46.23 μM
TOX21_GNRHR_HEK293_Agonist	Kidney	Human	2798	GNRHR	Gain	20.35 μM
TOX21_AR_BLA_Antagonist_ratio	Kidney	Human	367	AR	Loss	0.06 μM
TOX21_Aromatase_LUC_Antagonist	Breast	Human	1588	CYP19A1	Loss	0.04 μM
TOX21_GR_BLA_Antagonist_ratio	Cervix	Human	2908	NR3C1	Loss	67.66 μM
TOX21_TR_LUC_GH3_Antagonist	Pituitary gland	Rat	7067\|7068	THRA\|THRB	Loss	0.04 μM
TOX21_TSHR_HTRF_Agonist_ratio	Kidney	Human	7253	TSHR	Gain	15.0 μM
TOX21_TSHR_HTRF_Antagonist_ratio	Kidney	Human	7253	TSHR	Loss	87.18 μM
TOX21_AChE_Fluor_Antagonist	Bone	Human	43	ACHE	Loss	7.53 μM
TOX21_TR_LUC_GH3_Antagonist_Followup	Pituitary gland	Rat	7067\|7068	THRA\|THRB	Loss	24.33 μM
TOX21_TRHR_HEK293_Antagonist	Kidney	Human	7201	TRHR	Loss	39.61 μM
TOX21_p450_CYP3A4_Antagonist		Human	1576	CYP3A4	Loss	50.72 μM
TOX21_p450_CYP2D6_Antagonist		Human	1565	CYP2D6	Loss	42.02 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	11.83 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	6.29 μM
TOX21_p450_CYP1A2_Antagonist		Human	1544	CYP1A2	Loss	4.62 μM
TOX21_hERG_U2OS_Antagonist	Bone	Human	3757	KCNH2	Loss	37.24 μM

No ToxCast endpoints for intended target type: Molecular messenger

ToxCast endpoints for intended target type: Pathway

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist	Bone	Human	367	AR	Loss	12.64 μM
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist	Bone	Human	367	AR	Loss	9.92 μM
APR_HepG2_MitoticArrest_72hr	Liver	Human	3020	H3-3A	Inhibitory	19.84 μM
APR_HepG2_P-H2AX_72hr	Liver	Human	3014	H2AX	Inhibitory	0.09 μM
ACEA_ER_80hr	Breast	Human	2099	ESR1	Gain	2.06 μM
OT_AR_ARSRC1_0960	Kidney	Human	367\|6714	AR\|SRC	Gain	26.17 μM
OT_ERa_GFPERaERE_0120	Cervix	Human	2099	ESR1	Gain	90.72 μM
OT_ERa_GFPERaERE_0480	Cervix	Human	2099	ESR1	Gain	83.38 μM
ACEA_AR_antagonist_80hr	Prostate	Human	367	AR	Loss	20.63 μM
TOX21_p53_BLA_p2_ratio	Intestinal	Human	7157	TP53	Gain	32.99 μM
TOX21_p53_BLA_p3_ratio	Intestinal	Human	7157	TP53	Gain	28.5 μM
TOX21_FXR_BLA_Antagonist_ratio	Kidney	Human	9971	NR1H4	Loss	0.12 μM
TOX21_HDAC_LUC_Antagonist	Colon	Human	3065	HDAC1	Loss	7.28 μM
TOX21_p53_BLA_p1_ratio	Intestinal	Human	7157	TP53	Gain	85.64 μM
TOX21_FXR_BLA_Antagonist_ratio	Kidney	Human	9971	NR1H4	Loss	0.1 μM
TOX21_PPARd_BLA_Antagonist_ratio	Kidney	Human	5467	PPARD	Loss	0.09 μM
TOX21_HDAC_LUC_Antagonist	Colon	Human	3065	HDAC1	Loss	5.44 μM
TOX21_HRE_BLA_Agonist_ratio	Cervix	Human	3091	HIF1A	Gain	61.02 μM
TOX21_SHH_3T3_GLI3_LUC_Antagonist	Embryo	Mouse	6469	SHH	Loss	0.05 μM
TOX21_HSE_BLA_Agonist_ratio	Cervix	Human	3297	HSF1	Gain	0.06 μM
TOX21_FXR_BLA_Antagonist_ratio	Kidney	Human	9971	NR1H4	Loss	0.04 μM
TOX21_p53_BLA_p5_ratio	Intestinal	Human	7157	TP53	Gain	77.04 μM
TOX21_HDAC_LUC_Antagonist	Colon	Human	3065	HDAC1	Loss	8.37 μM
TOX21_HRE_BLA_Agonist_ratio	Cervix	Human	3091	HIF1A	Gain	56.62 μM

ToxCast endpoints for intended target type: Cellular

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
APR_HepG2_MicrotubuleCSK_24hr	Liver	Human	7846	TUBA1A	Inhibitory	17.61 μM
APR_HepG2_MicrotubuleCSK_72hr	Liver	Human	7846	TUBA1A	Inhibitory	3.39 μM
TOX21_CASP3_HEPG2	Liver	Human	836	CASP3	Gain	0.1 μM

No ToxCast endpoints for intended target type: Hormone

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.